GlassScriptPhysician profile
Michelle D Conger
NPI 1730152703
$1,434.39
in general payments reported to CMS, 2019-2025
18 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,031 · 2020: $392 · 2022: $11.85.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $234.60 | 2019-2020 | |
| Biogen, INC. | $210.86 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $161.77 | 2019-2020 | |
| Novo Nordisk INC | $140.48 | 2019-2020 | |
| Glaxosmithkline, LLC. | $126.25 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $125.02 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $96.20 | 2019-2020 | |
| Amgen INC. | $76.06 | 2019 | |
| Amarin Pharma, INC. | $48.13 | 2019 | |
| Janssen Pharmaceuticals, INC | $35.71 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $29.82 | 2019 | |
| Daiichi Sankyo INC. | $29.12 | 2019-2020 | |
| Ascensia Diabetes Care US INC. | $28.50 | 2019 | |
| Circassia INC. | $27.86 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $21.32 | 2019 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Roche Diabetes Care, INC. | $19.42 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $16.64 | 2020 | |
| Ultragenyx Pharmaceutical INC. | $6.63 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michelle Conger listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.